Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
STA Pharmaceutical, a subsidiary of WuXi AppTec, and Dizal Pharmaceutical have announced a strategic partnership.
read more
Wednesday, March 06, 2019
STA Pharmaceutical, a subsidiary of WuXi AppTec, and Ark Biosciences announced a strategic partnership for CMC development and manufacturing.
read more
STA Pharmaceutical announced its partner, Ascletis has received approval from China Food and Drug Administration of its Category 1 new drug, Ganovo, to treat viral hepatitis C.
read more
Tuesday, February 09, 2021
WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland.
read more
STA Pharmaceutical has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.
read more
WuXi STA announced the opening of its large-scale oligonucleotide API manufacturing facility in Changzhou, China.
read more
WuXi STA, a subsidiary of WuXi AppTec, announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus.
read more
STA Pharmaceutical announces that its API R&D and manufacturing facility located in Changzhou, China has secured Pre-Approval Inspection for two APIs from the FDA – with no Form 483s issued.
read more
Thursday, November 21, 2019
Under the terms of this agreement, WuXi STA will become the preferred Contract Development and Manufacturing Organization (CDMO) partner of Impact Therapeutics.
read more
Thursday, December 01, 2022
WuXi STA, a subsidiary of WuXi AppTec announced the partnership with Multiply Labs (based in San Francisco, CA, USA), a robotics company that has developed industry-leading automated manufacturing systems to produce individualized drugs.
read more
Wednesday, December 02, 2020
WuXi Advanced Therapies announced the completion of a facility expansion that will triple its advanced testing capacity at the company's Philadelphia Navy Yard campus.
read more
WuXi Biologics and Immune Pharmaceuticals announced a development and manufacturing agreement for the production of bertilimumab, Immune's first-in-class anti-eotaxin-1 monoclonal antibody.
read more
Wednesday, March 21, 2018
WuXi Biologics has selected 4,000 liter (L) Custom Single Run (CSR) disposable bioreactors from ABEC for its new commercial manufacturing facility (MFG4) in Wuxi city, Jiangsu, China.
read more
WuXi Biologics has entered into a strategic partnership LOI with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.
read more
Friday, February 14, 2020
WuXi Biologics has released the following statement addressing the Coronavirus outbreak.
read more